Gain Therapeutics’ Post

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/epbYkP28

#SfN23 is approaching, and I am looking forward to seeing you in Washinton, DC! If you are also attending, please stop by Booth#1903 and don’t miss the chance to learn how ICE Bioscience and our team can accelerate your research studies by discovering our in vitro & in vivo CNS services and exploring our pioneering offerings!   ICE Bioscience established multiple platforms (protein engineering, cell line development, target validation, translational neuroscience, DMPK, etc) to enable us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in the fields of Immuno-Oncology, Cardiovascular diseases and Neuroscience (Pain/Neuropsychiatry/Epilepsy/Neurodegeneration/Stroke, etc).   Join us and connect, collaborate and contribute! 🤝 🤝 🤝 #sfn23 #neuroscience #cns #neurologicaldisorders #drugdiscovery #pharmaceuticals #biotech #cro #ionchannels #electrophysiology #eeg #invivo #invitro

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/eWGeWyPY

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/gSMcnfF6

Our latest publication in CNS Neuroscience & Therapeutics is out now!! ✨✨✨ you can read our very interesting findings on statins' role in parkinson's disease here https://lnkd.in/ddkbP9TT

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/erNMsDVi

Our new neuroscience brochure is now available for you to download for insight into: 💡Panel of models with increasing complexity and translational relevance: • Cell lines for central and peripheral nervous system targets. • Primary neuronal cultures, such as dissociated cortical, trigeminal or DRG. • CNS drug discovery to understand the effects of test compounds on brain slice tissue. • Human iPSC-derived neurons. 💡Range of assay methodologies to help you investigate the mechanism of action for pre-clinical compounds, confirm compound effects, address the neurotoxicity of compounds and assess the effects of compounds on a range of excitability parameters: • Heterologous cell lines and integrative assays. • Selectivity and safety profiling of lead compounds and IND candidates. • Translational assays: central and peripheral neuronal firing, and native ion channel screening assays. 💡Studying ion channels on the lysosomal membrane. 💡CNS drug discovery to understand the effects of test compounds on brain slice tissue. 📄Case study: Multi-assay high-throughput repurposing screen for rare epilepsy mutation in KCNC1 gene. As a specialist preclinical drug discovery CRO, we pride ourselves on delivering high quality data, on time and on budget. Find out more about our neuroscience services and download the brochure: https://hubs.la/Q02GXJCC0 Contact us to request a meeting or quote: https://hubs.la/Q02GXhnX0 #neuroscience #drugdiscovery #cro #ionchannels #lifesciences #cns #electrophysiology

Missed this exciting update in neurodegenerative drug development? 🧠✨ In their recent article, Certara's Hugo Geerts, Piet Van Der Graaf, Silke Bergeler from BMS, and SUNY professor, William Lytton explore the challenges of neurodegenerative diseases, marked by scarce biomarkers and subjective assessments. Their breakthrough? Integrating Computational Neurosciences' predictions with QSP's insights, boosting success rates in drug development. Read more about how this methodology paves the way for innovative therapeutic interventions: https://ow.ly/FpIp50Q0huT #Neuroscience #DrugDevelopment #ComputationalModeling #QSP

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3DrG0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H44NX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Exciting news in neuroscience diagnostics! Fujirebio Diagnostics, Inc. has launched the Lumipulse G GFAP assay in the US, a groundbreaking tool for researchers studying neurological conditions. This fully automated Chemiluminescent Enzyme Immunoassay (CLEIA) test quantitatively measures glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc., states: "We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine." This launch further solidifies Fujirebio's position as a leader in neuro biomarker testing, following their 2023 introductions of NfL and pTau 217 assays. https://lnkd.in/euNv5Sat 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCare #Neuroscience #Diagnostics #MedicalInnovation